In this on-demand webinar, Professor Stephen Palmer from the University of York discusses his work on the assessment of regenerative medicines and cell therapy, and the UK and EU payer perspective on the potential value of these therapies.
- Value-based pricing is expected by everyone, but which indications have the head-room to allow for higher-cost technologies?
- How does the value of a CAR-T vary between indications? Will we see price erosion as more products come to market?
- How do manufacturers need to think about treatment sequencing and combinations during development?
– Professor Stephen Palmer – University of York, UK